1
|
Lecollinet S, Richardson J. Vaccination against the feline immunodeficiency virus: the road not taken. Comp Immunol Microbiol Infect Dis 2007; 31:167-90. [PMID: 17706778 DOI: 10.1016/j.cimid.2007.07.007] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/12/2007] [Indexed: 11/28/2022]
Abstract
Natural infection of domestic cats by the feline immunodeficiency virus (FIV) causes acquired immunodeficiency syndrome (AIDS). FIV is genetically related to human immunodeficiency virus (HIV), and the clinical and biological features of infections caused by feline and human viruses in their respective hosts are highly analogous. Although the obstacles to vaccinating against FIV and HIV would seem to be of comparable difficulty, a licensed vaccine against feline AIDS is already in widespread use in several countries. While this seemingly major advance in prevention of AIDS would appear to be highly instructive for HIV vaccine development, its message has not been heeded by investigators in the HIV field. This review endeavours to relate what has been learned about vaccination against feline AIDS, and to suggest what this may mean for HIV vaccine development.
Collapse
Affiliation(s)
- Sylvie Lecollinet
- UMR 1161 Virologie INRA-AFSSA-ENVA, Ecole Nationale Vétérinaire d'Alfort, 7 avenue du Général de Gaulle, 94700 Maisons-Alfort, France
| | | |
Collapse
|
2
|
Giannecchini S, D'Ursi AM, Esposito C, Scrima M, Zabogli E, Freer G, Rovero P, Bendinelli M. Antibodies generated in cats by a lipopeptide reproducing the membrane-proximal external region of the feline immunodeficiency virus transmembrane enhance virus infectivity. CLINICAL AND VACCINE IMMUNOLOGY : CVI 2007; 14:944-51. [PMID: 17596431 PMCID: PMC2044484 DOI: 10.1128/cvi.00140-07] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The immunogenicity of a lipoylated peptide (lipo-P59) reproducing the membrane-proximal external region (MPER) of the transmembrane glycoprotein of feline immunodeficiency virus (FIV) was investigated with cats. In the attempt to mimic the context in which MPER is located within intact virions, lipo-P59 was administered in association with membrane-like micelles. Analyses showed that in this milieu, lipo-P59 had a remarkable propensity to be positioned at the membrane interface, displayed a large number of ordered structures folded in turn helices, and was as active as lipo-P59 alone at inhibiting FIV infectivity in vitro. The antibodies developed differed from the ones previously obtained by immunizing cats with the nonlipoylated version of the peptide (G. Freer, S. Giannecchini, A. Tissot, M. F. Bachmann, P. Rovero, P. F. Serres, and M. Bendinelli, Virology 322:360-369, 2004) in epitope specificity and in the fact that they bound FIV virions. However, they too lacked virus-neutralizing activity and actually enhanced FIV infectivity for lymphoid cell cultures. It is concluded that the use of MPER-reproducing oligopeptides is not a viable approach for vaccinating against FIV.
Collapse
Affiliation(s)
- Simone Giannecchini
- Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, I-56127 Pisa, Italy
| | | | | | | | | | | | | | | |
Collapse
|
3
|
FIV as a Model for HIV: An Overview. IN VIVO MODELS OF HIV DISEASE AND CONTROL 2007. [PMCID: PMC7121254 DOI: 10.1007/0-387-25741-1_7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Animal models for human immunodeficiency virus (HIV) infection play a key role in understanding the pathogenesis of AIDS and the development of therapeutic agents and vaccines. As the only lentivirus that causes an immunodeficiency resembling that of HIV infection, in its natural host, feline immunodeficiency virus (FIV) has been a unique and powerful model for AIDS research. FIV was first described in 1987 by Niels Pedersen and co-workers as the causative agent for a fatal immunodeficiency syndrome observed in cats housed in a cattery in Petaluma, California. Since this landmark observation, multiple studies have shown that natural and experimental infection of cats with biological isolates of FIV produces an AIDS syndrome very similar in pathogenesis to that observed for human AIDS. FIV infection induces an acute viremia associated with Tcell alterations including depressed CD4 :CD8 T-cell ratios and CD4 T-cell depletion, peripheral lymphadenopathy, and neutropenia. In later stages of FIV infection, the host suffers from chronic persistent infections that are typically self-limiting in an immunocompetent host, as well as opportunistic infections, chronic diarrhea and wasting, blood dyscracias, significant CD4 T-cell depletion, neurologic disorders, and B-cell lymphomas. Importantly, chronic FIV infection induces a progressive lymphoid and CD4 T-cell depletion in the infected cat. The primary mode of natural FIV transmission appears to be blood-borne facilitated by fighting and biting. However, experimental infection through transmucosal routes (rectal and vaginal mucosa and perinatal) have been well documented for specific FIV isolates. Accordingly, FIV disease pathogenesis exhibits striking similarities to that described for HIV-1 infection.
Collapse
|
4
|
Broche-Pierre S, Richardson J, Moraillon A, Sonigo P. Evaluation of live feline immunodeficiency virus vaccines with modified antigenic properties. J Gen Virol 2005; 86:2495-2506. [PMID: 16099908 DOI: 10.1099/vir.0.80469-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Live-attenuated viruses have typically been generated from pathogenic viruses by genetic modifications that modified their replicative capacity. The present study investigated whether modification of the antigenic properties of live-attenuated viruses might improve upon the protection that such vaccines afford against lentivirus infection. In a previous study, random amino acid substitutions were introduced into the transmembrane envelope glycoprotein of the feline immunodeficiency virus (FIV), within a highly conserved domain (principal immunodominant domain) bearing immunodominant B-cell epitopes. Amongst a wide set of mutants, mutations that modified antibody specificity without abolishing infectivity ex vivo were selected. In the present study, two such mutants, TN14 and TN92, were evaluated for their replicative capacities and pathogenic properties in vivo in comparison with the parental virus, FIV 34TF10. No significant differences in viral load were observed between mutant and parental viruses. After 1 year of infection, all animals were subjected to a heterologous intraclade superinfection with a primary strain of FIV. Whilst both parental and modified viruses protected cats from high viral loads after superinfection, the TN92 virus afforded a higher degree of protection (P=0·0079). Such improvement in protection might correlate with a decrease in the immunogenicity of a B-cell epitope potentially involved in antibody enhancement of infection.
Collapse
MESH Headings
- Amino Acid Sequence
- Amino Acid Substitution
- Animals
- Antibodies, Viral/blood
- Base Sequence
- Cat Diseases/immunology
- Cat Diseases/prevention & control
- Cat Diseases/virology
- Cats
- Epitopes, B-Lymphocyte/immunology
- Gene Products, env/administration & dosage
- Gene Products, env/genetics
- Gene Products, env/immunology
- Immunodeficiency Virus, Feline/genetics
- Immunodeficiency Virus, Feline/immunology
- Immunodeficiency Virus, Feline/pathogenicity
- Immunodominant Epitopes/immunology
- Lentivirus Infections/immunology
- Lentivirus Infections/prevention & control
- Lentivirus Infections/veterinary
- Lentivirus Infections/virology
- Molecular Sequence Data
- Vaccination
- Vaccines, Attenuated/administration & dosage
- Vaccines, Attenuated/immunology
- Vaccines, DNA/administration & dosage
- Vaccines, DNA/immunology
- Viral Vaccines/administration & dosage
- Viral Vaccines/immunology
Collapse
Affiliation(s)
- Sophie Broche-Pierre
- Génétique des Virus, Institut Cochin (INSERM U567, CNRS UMR8104), 22 rue Méchain, 75014 Paris, France
| | - Jennifer Richardson
- Génétique des Virus, Institut Cochin (INSERM U567, CNRS UMR8104), 22 rue Méchain, 75014 Paris, France
| | - Anne Moraillon
- UMR INRA-ENVA-AFSSA 1161 de Virologie, Ecole Nationale Vétérinaire d'Alfort (ENVA), 7 rue du Général de Gaulle, 94704 Maisons-Alfort, France
| | - Pierre Sonigo
- Génétique des Virus, Institut Cochin (INSERM U567, CNRS UMR8104), 22 rue Méchain, 75014 Paris, France
| |
Collapse
|
5
|
Huisman W, Schrauwen EJA, Pas SD, Karlas JA, Rimmelzwaan GF, Osterhaus ADME. Antibodies specific for hypervariable regions 3 to 5 of the feline immunodeficiency virus envelope glycoprotein are not solely responsible for vaccine-induced acceleration of challenge infection in cats. J Gen Virol 2004; 85:1833-1841. [PMID: 15218167 DOI: 10.1099/vir.0.79949-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
In a previous vaccination study in cats, the authors reported on accelerated feline immunodeficiency virus (FIV) replication upon challenge in animals vaccinated with a candidate envelope subunit vaccine. Plasma transfer studies as well as antibody profiles in vaccinated cats indicated a causative role for antibodies directed against the hypervariable regions HV3, HV4 and HV5 (HV3-5) of the envelope glycoprotein. The present study was designed to investigate further the contribution of antibodies in envelope vaccine-induced acceleration of FIV infection. To this end, regions HV3-5 of the envelope glycoprotein were deleted from the original vaccine, thus addressing the contributing role of antibodies directed against these hypervariable regions. Interestingly, this approach did not prevent acceleration of challenge infection. Analysis of the antibody responses in the respective groups suggested that removal of HV3-5 redirected the humoral immune response towards other regions of the envelope glycoprotein, indicating that these regions can also induce antibodies that accelerate virus replication.
Collapse
Affiliation(s)
- Willem Huisman
- Erasmus MC, Institute of Virology, PO Box 1738, 3000 DR Rotterdam, The Netherlands
| | - Eefje J A Schrauwen
- Erasmus MC, Institute of Virology, PO Box 1738, 3000 DR Rotterdam, The Netherlands
| | - Suzan D Pas
- Erasmus MC, Institute of Virology, PO Box 1738, 3000 DR Rotterdam, The Netherlands
| | - Jos A Karlas
- Erasmus MC, Institute of Virology, PO Box 1738, 3000 DR Rotterdam, The Netherlands
| | - Guus F Rimmelzwaan
- Erasmus MC, Institute of Virology, PO Box 1738, 3000 DR Rotterdam, The Netherlands
| | | |
Collapse
|
6
|
Freer G, Giannecchini S, Tissot A, Bachmann MF, Rovero P, Serres PF, Bendinelli M. Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein. Virology 2004; 322:360-9. [PMID: 15110533 DOI: 10.1016/j.virol.2004.02.017] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2003] [Revised: 02/17/2004] [Accepted: 02/17/2004] [Indexed: 11/27/2022]
Abstract
Immunogenicity of the tryptophan-rich motif (TrpM) in the membrane-proximal ectodomain of the transmembrane (TM) glycoprotein of feline immunodeficiency virus (FIV) was investigated. Peptide 59, a peptide containing the TrpM of the TM of FIV, was covalently coupled to Qbeta phage virus-like particles (Qbeta-59) in the attempt to induce potent anti-TrpM B cell responses in cats. All Qbeta-59 immunized cats, but not cats that received a mixture of uncoupled Qbeta and peptide 59, developed antibodies that reacted with a same epitope in extensive binding and binding competition assays. The epitope recognized was composed of three amino acids, two of which are adjacent. However, Qbeta-59-immune sera failed to recognize whole FIV in all binding and neutralization assays performed. Furthermore, no reactivity against the TrpM was detected by screening sera from FIV-infected cats that had reacted with TM peptides, confirming that this epitope does not seem to be serologically functional in the FIV virion. The data suggest that TrpM may not be a suitable target for antiviral vaccine design.
Collapse
Affiliation(s)
- Giulia Freer
- Department of Experimental Pathology, University of Pisa, I-56127 Pisa, Italy
| | | | | | | | | | | | | |
Collapse
|
7
|
Giannecchini S, Bonci F, Pistello M, Matteucci D, Sichi O, Rovero P, Bendinelli M. The membrane-proximal tryptophan-rich region in the transmembrane glycoprotein ectodomain of feline immunodeficiency virus is important for cell entry. Virology 2004; 320:156-66. [PMID: 15003871 DOI: 10.1016/j.virol.2003.12.001] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2003] [Revised: 12/01/2003] [Accepted: 12/02/2003] [Indexed: 11/22/2022]
Abstract
The mechanisms whereby feline immunodeficiency virus (FIV) adsorbs and enters into susceptible cells are poorly understood. Here, we investigated the role exerted in such functions by the tryptophan (Trp)-rich motif present membrane-proximally in the ectodomain of the FIV transmembrane glycoprotein. Starting from p34TF10, which encodes the entire genome of FIV Petaluma, we produced 11 mutated clones having the Trp-rich motif scrambled or variously deleted or substituted. All mutated progenies adsorbed normally to cells, but the ones with severe disruptions of the motif failed to generate proviral DNA. In the latter mutants, proviral DNA formation was restored by providing an independent source of intact FIV envelope glycoproteins or by addition of the fusing agent polyethylene glycol, thus clearly indicating that their defect resided primarily at the level of cell entry. In addition, the replication-competent mutants exhibited a generally enhanced susceptibility to selected entry inhibitory synthetic peptides, suggestive of a reduced efficiency of the entry step.
Collapse
Affiliation(s)
- Simone Giannecchini
- Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, I-56127 Pisa, Italy
| | | | | | | | | | | | | |
Collapse
|
8
|
Giannecchini S, Di Fenza A, D'Ursi AM, Matteucci D, Rovero P, Bendinelli M. Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein. J Virol 2003; 77:3724-33. [PMID: 12610147 PMCID: PMC149492 DOI: 10.1128/jvi.77.6.3724-3733.2003] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
Feline immunodeficiency virus (FIV) provides a valuable animal model by which criteria for lentivirus control strategies can be tested. Previous studies have shown that a 20-mer synthetic peptide of the membrane-proximal ectodomain of FIV transmembrane glycoprotein, designated peptide 59, potently inhibited the growth of tissue culture-adapted FIV in feline fibroblastoid CrFK cells. In the present report we describe the potential of this peptide to inhibit the replication of primary FIV isolates in lymphoid cells. Because antiviral activity of peptide 59 was found to map to a short segment containing three conserved Trp residues, further analyses focused on a derivative of eight amino acids ((770)W-I(777)), designated C8. Peptide C8 activity was found to be dependent on conservation of the Trp motif, to be removed from solution by FIV absorbed onto substrate cells, and to be blocked by a peptide derived from the N-terminal portion of FIV transmembrane glycoprotein. Structural studies showed that peptide C8 possesses a conformational propensity highly uncommon for peptides of its size, which may account for its considerable antiviral potency in spite of small size.
Collapse
Affiliation(s)
- Simone Giannecchini
- Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, I-56127 Pisa, Department of Pharmaceutical Sciences, University of Salerno, I-84084 Fisciano, Italy, Mymetics Corporation, Annapolis, Maryland
| | - Armida Di Fenza
- Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, I-56127 Pisa, Department of Pharmaceutical Sciences, University of Salerno, I-84084 Fisciano, Italy, Mymetics Corporation, Annapolis, Maryland
| | - Anna Maria D'Ursi
- Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, I-56127 Pisa, Department of Pharmaceutical Sciences, University of Salerno, I-84084 Fisciano, Italy, Mymetics Corporation, Annapolis, Maryland
| | - Donatella Matteucci
- Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, I-56127 Pisa, Department of Pharmaceutical Sciences, University of Salerno, I-84084 Fisciano, Italy, Mymetics Corporation, Annapolis, Maryland
| | - Paolo Rovero
- Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, I-56127 Pisa, Department of Pharmaceutical Sciences, University of Salerno, I-84084 Fisciano, Italy, Mymetics Corporation, Annapolis, Maryland
| | - Mauro Bendinelli
- Retrovirus Center and Virology Section, Department of Experimental Pathology, University of Pisa, I-56127 Pisa, Department of Pharmaceutical Sciences, University of Salerno, I-84084 Fisciano, Italy, Mymetics Corporation, Annapolis, Maryland
- Corresponding author. Mailing address: Dipartimento di Patologia Sperimentale, Università di Pisa, Via San Zeno 37, I-56127 Pisa, Italy. Phone: 39-050-2213641. Fax: 39-050-2213639. E-mail:
| |
Collapse
|
9
|
Goto Y, Nishimura Y, Baba K, Mizuno T, Endo Y, Masuda K, Ohno K, Tsujimoto H. Association of plasma viral RNA load with prognosis in cats naturally infected with feline immunodeficiency virus. J Virol 2002; 76:10079-83. [PMID: 12208990 PMCID: PMC136479 DOI: 10.1128/jvi.76.19.10079-10083.2002] [Citation(s) in RCA: 22] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
We measured the quantity of plasma feline immunodeficiency virus (FIV) RNA using a real-time sequence detecting system. Plasma viral RNA load was shown to correlate with the clinical stage, survival time, and disease progression in naturally FIV-infected cats. The present study indicates that the plasma viral RNA load can be used as a clinical marker representing the impairment of the immune system and predicting the clinical outcome in FIV-infected cats.
Collapse
Affiliation(s)
- Yuko Goto
- Department of Veterinary Internal Medicine, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Bunkyo-ku, Tokyo 113-8657, Japan
| | | | | | | | | | | | | | | |
Collapse
|
10
|
Richardson J, Broche S, Baud S, Leste-Lasserre T, Féménia F, Levy D, Moraillon A, Pancino G, Sonigo P. Lymphoid activation: a confounding factor in AIDS vaccine development? J Gen Virol 2002; 83:2515-2521. [PMID: 12237435 DOI: 10.1099/0022-1317-83-10-2515] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
In a previous vaccination trial, inoculation of env gene DNA failed to elicit a detectable antibody response, yet accelerated virus dissemination in most immunized cats following challenge with feline immunodeficiency virus. This result raised the possibility that cell-mediated immune responses had given rise to immune-mediated enhancement of infection. Since high-level replication of immunodeficiency viruses in lymphocytes requires cellular activation, antigen-specific responses or non-specific polyclonal activation may have increased the frequency of optimal target cells. In the present DNA vaccination trial, although designed so as to minimize non-specific polyclonal activation, immune-mediated enhancement was nonetheless observed in certain immunized cats. Moreover, rapid virus dissemination in vivo was associated with the presence of T-helper responses prior to challenge, and was linked to increased susceptibility of lymphocytes to ex vivo infection. Immune activation may thus be a confounding factor in vaccination against lentivirus infection, diminishing vaccine efficacy and giving rise to immune-mediated enhancement.
Collapse
Affiliation(s)
- Jennifer Richardson
- Génétique des Virus, Institut Cochin (INSERM U567 CNRS UMR 8104), 22 rue Méchain, 75014 Paris, France1
| | - Sophie Broche
- Génétique des Virus, Institut Cochin (INSERM U567 CNRS UMR 8104), 22 rue Méchain, 75014 Paris, France1
| | - Sandrine Baud
- Génétique des Virus, Institut Cochin (INSERM U567 CNRS UMR 8104), 22 rue Méchain, 75014 Paris, France1
| | - Thierry Leste-Lasserre
- Génétique des Virus, Institut Cochin (INSERM U567 CNRS UMR 8104), 22 rue Méchain, 75014 Paris, France1
| | - Françoise Féménia
- Génétique des Virus, Institut Cochin (INSERM U567 CNRS UMR 8104), 22 rue Méchain, 75014 Paris, France1
| | - Daniel Levy
- Génétique des Virus, Institut Cochin (INSERM U567 CNRS UMR 8104), 22 rue Méchain, 75014 Paris, France1
| | - Anne Moraillon
- Génétique des Virus, Institut Cochin (INSERM U567 CNRS UMR 8104), 22 rue Méchain, 75014 Paris, France1
| | - Gianfranco Pancino
- Génétique des Virus, Institut Cochin (INSERM U567 CNRS UMR 8104), 22 rue Méchain, 75014 Paris, France1
| | - Pierre Sonigo
- Génétique des Virus, Institut Cochin (INSERM U567 CNRS UMR 8104), 22 rue Méchain, 75014 Paris, France1
| |
Collapse
|
11
|
Edgeworth RL, San JH, Rosenzweig JA, Nguyen NL, Boyer JD, Ugen KE. Vaccine development against HIV-1: current perspectives and future directions. Immunol Res 2002; 25:53-74. [PMID: 11868934 DOI: 10.1385/ir:25:1:53] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Abstract
The development of an efficacious vaccine against the human immunodeficiency virus (HIV) is of great urgency, because it is accepted that vaccination is the only means capable of controlling the AIDS pandemic. The foundation of HIV vaccine development is the analysis of immune responses during natural infection and the utilization of this knowledge for the development of protective immunization strategies. Initial vaccine development and experimentation are usually in animal models, including murine, feline, and nonhuman primates. Experimental vaccine candidates are closely studied for both efficacy and safety before proceeding to human clinical trials. There are a number of different therapeutic and prophylactic vaccine strategies currently being studied in human clinical trials. Vaccine strategies that are being tested, or have previously been tested, in humans include subunit, DNA plasmid, and viral vector, and combinations of these various strategies. Some of the results of these trials are promising, and additional research has focused on the development of appropriate chemical and genetic adjuvants as well as methods of vaccine delivery to improve the host immune response. This review summarizes the vaccine strategies that have been tested in both animal models and human clinical trials.
Collapse
Affiliation(s)
- Rebecca L Edgeworth
- Department of Medical Microbiology and Immunology, University of South Florida, College of Medicine, Tampa 33612, USA
| | | | | | | | | | | |
Collapse
|
12
|
Pistello M, Moscardini M, Mazzetti P, Bonci F, Zaccaro L, Isola P, Freer G, Specter S, Matteucci D, Bendinelli M. Development of feline immunodeficiency virus ORF-A (tat) mutants: in vitro and in vivo characterization. Virology 2002; 298:84-95. [PMID: 12093176 DOI: 10.1006/viro.2002.1442] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
Abstract
A functional ORF-A is essential for efficient feline immunodeficiency virus replication in lymphocytes. We have characterized a series of mutants of the Petaluma strain, derived from p34TF10 and having different combinations of stop codons and increasingly long deletions in ORF-A. Six clones proved fully replicative in fibroblastoid Crandell feline kidney cells and monocyte-derived macrophage cultures but failed to replicate in T cell lines and primary lymphoblasts. Cats inoculated with three selected mutants had considerably milder infections than controls given intact ORF-A virus. In vivo, the mutants maintained growth properties similar to those in vitro for at least 7 months, except that replication in lymphoid cells was strongly reduced but not ablated. One mutant underwent extensive ORF-A changes without, however, reverting to wild-type. Antiviral immune responses were feeble in all cats, suggesting that viral loads were too low to represent a sufficiently powerful antigenic stimulus.
Collapse
Affiliation(s)
- M Pistello
- Retrovirus Center and Virology Section, University of Pisa, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Bendinelli M, Pistello M, Del Mauro D, Cammarota G, Maggi F, Leonildi A, Giannecchini S, Bergamini C, Matteucci D. During readaptation in vivo, a tissue culture-adapted strain of feline immunodeficiency virus reverts to broad neutralization resistance at different times in individual hosts but through changes at the same position of the surface glycoprotein. J Virol 2001; 75:4584-93. [PMID: 11312328 PMCID: PMC114211 DOI: 10.1128/jvi.75.10.4584-4593.2001] [Citation(s) in RCA: 20] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The broad resistance to antibody-mediated neutralization of lentiviruses recently isolated from infected hosts is a poorly understood feature which might contribute to the ability of these viruses to persist and to the failure of experimental vaccines to protect against virulent viruses. We studied the underlying molecular mechanisms by examining the evolution of a neutralization-sensitive, tissue culture-adapted strain of feline immunodeficiency virus upon reinoculation into specific-pathogen-free cats. Reversion to broad neutralization resistance was observed in seven of seven inoculated animals and, in individual hosts, started to develop between less than 4 and more than 15 months from infection. After comparison of the envelope sequences of the inoculum virus, of an additional 4 neutralization-sensitive in vitro variants, and of 14 ex vivo-derived variants (6 neutralization sensitive, 5 resistant, and 3 with intermediate phenotype), a Lys-->Asn or -->Glu change at position 481 in the V4 region of the surface glycoprotein appeared as a key player in the reversion. This conclusion was confirmed by mutagenesis of molecularly cloned virus. Analysis of viral quasispecies and biological clones showed that the intermediate phenotype was due to transient coexistence of neutralization-sensitive and -resistant variants. Since the amino acid position involved was the same in four of four recent revertants, it is suggested that the number of residues that control reversion to broad neutralization resistance in FIV might be very limited. Amino acid 481 was found to be changed only in one of three putative long-term revertants. These variants shared a Ser-->Asn change at position 557 in region V5, which probably collaborated with other mutations in long-term maintenance of neutralization resistance, as suggested by the study of mutagenized virus.
Collapse
Affiliation(s)
- M Bendinelli
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Briquet S, Richardson J, Vanhée-Brossollet C, Vaquero C. Natural antisense transcripts are detected in different cell lines and tissues of cats infected with feline immunodeficiency virus. Gene 2001; 267:157-64. [PMID: 11313142 DOI: 10.1016/s0378-1119(01)00404-8] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
Feline immunodeficiency virus (FIV) is a lentivirus inducing an AIDS-like disease in cats, thus providing an interesting model for AIDS study. FIV and HIV-1 possess a similar genomic arrangement of structural and non-structural genes, whose expression is regulated by related genetic mechanisms. On the DNA strand complementary to the HIV-1 envelope messenger, an open reading frame (ORF) has been identified which encompasses the Rev Responsive Element (RRE), a cis-acting element critical to HIV gene expression. This ORF was highly conserved among HIV-1 isolates and had the potential to encode a hydrophobic protein. A corresponding antisense transcript was detected in cells infected with HIV-1, and appeared to encode an antisense protein. In the present study, we have identified a well-conserved antisense ORF, also coincident with the RRE region, in the genome of 21 FIV isolates. The predicted protein, 103 amino acids in length, is highly hydrophobic, as is the case for that of HIV-1. In addition, we have shown that a corresponding transcript, complementary to the transmembrane sequence of the FIV envelope gene, was produced in different cellular and viral contexts, that is, ex vivo and in vivo in FIV infected cell lines and tissues of infected cats, respectively. Expression of antisense transcripts might therefore be of general importance in the natural history of retroviruses.
Collapse
Affiliation(s)
- S Briquet
- INSERM U511, CHU Pitié-Salpêtrière, 91 boulevard de l'Hôpital, 75013 Paris, France
| | | | | | | |
Collapse
|
15
|
Bertoni G, Hertig C, Zahno ML, Vogt HR, Dufour S, Cordano P, Peterhans E, Cheevers WP, Sonigo P, Pancino G. B-cell epitopes of the envelope glycoprotein of caprine arthritis-encephalitis virus and antibody response in infected goats. J Gen Virol 2000; 81:2929-2940. [PMID: 11086124 DOI: 10.1099/0022-1317-81-12-2929] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Goats infected with caprine arthritis-encephalitis virus (CAEV) develop high titres of antibodies to Env. Not only is no consistent neutralizing response found but anti-Env antibodies have even been associated with disease in infected goats. To identify the continuous antigenic determinants involved in this atypical anti-Env response, we mapped CAEV-CO Env by screening an epitope expression library with infected goat sera. In addition to the four previously described epitopes, seven novel antigenic sites were identified, of which five were located on the surface (SU) and two in the transmembrane (TM) subunits of Env. The SU antibody-binding domains located in the variable regions of the C-terminal part of the molecule (SU3 to SU5) showed the strongest reactivity and induced a rapid seroconversion in six experimentally infected goats. However, the response to these immunodominant epitopes did not appear to be associated with any neutralizing activity. The pattern of serum reactivity of naturally infected goats with these epitopes was restricted, suggesting a type-specific reaction. Interestingly, the reactivity of peptides representing SU5 sequences derived from CAEV field isolates varied with the geographical and/or breeding origin of the animals. This suggests that peptides corresponding to the immunodominant SU epitopes may well be useful in the serotyping of CAEV isolates. Furthermore, the identification of the CAEV Env epitopes will permit us to functionally dissect the antibody response and to address the role of anti-Env antibodies either in the protection from or in the pathogenesis of CAEV infection.
Collapse
MESH Headings
- Amino Acid Sequence
- Animals
- Antibodies, Viral/biosynthesis
- Antibodies, Viral/immunology
- Antibody Specificity
- Antigens, Viral/chemistry
- Antigens, Viral/genetics
- Antigens, Viral/immunology
- Arthritis-Encephalitis Virus, Caprine/chemistry
- Arthritis-Encephalitis Virus, Caprine/genetics
- Arthritis-Encephalitis Virus, Caprine/immunology
- Arthritis-Encephalitis Virus, Caprine/physiology
- Binding Sites
- Blotting, Western
- Cloning, Molecular
- Epitope Mapping
- Epitopes, B-Lymphocyte/chemistry
- Epitopes, B-Lymphocyte/genetics
- Epitopes, B-Lymphocyte/immunology
- Gene Products, env/chemistry
- Gene Products, env/genetics
- Gene Products, env/immunology
- Glycoproteins
- Goats/immunology
- Goats/virology
- Immune Sera/biosynthesis
- Immune Sera/immunology
- Immunodominant Epitopes/chemistry
- Immunodominant Epitopes/genetics
- Immunodominant Epitopes/immunology
- Lentivirus Infections/immunology
- Lentivirus Infections/veterinary
- Membrane Proteins
- Molecular Sequence Data
- Neutralization Tests
- Peptide Library
- Protein Structure, Tertiary
- Recombinant Proteins/chemistry
- Recombinant Proteins/genetics
- Recombinant Proteins/immunology
- Sequence Alignment
- Time Factors
- Viral Proteins
Collapse
Affiliation(s)
- Giuseppe Bertoni
- Institute of Veterinary Virology, University of Berne, Länggass-Str. 122, CH-3012 Berne, Switzerland1
| | - Christian Hertig
- Institute of Veterinary Virology, University of Berne, Länggass-Str. 122, CH-3012 Berne, Switzerland1
| | - Marie-Luise Zahno
- Institute of Veterinary Virology, University of Berne, Länggass-Str. 122, CH-3012 Berne, Switzerland1
| | - Hans-Rudolf Vogt
- Institute of Veterinary Virology, University of Berne, Länggass-Str. 122, CH-3012 Berne, Switzerland1
| | - Sophie Dufour
- Institute of Veterinary Virology, University of Berne, Länggass-Str. 122, CH-3012 Berne, Switzerland1
| | - Pablo Cordano
- Institute of Veterinary Virology, University of Berne, Länggass-Str. 122, CH-3012 Berne, Switzerland1
| | - Ernst Peterhans
- Institute of Veterinary Virology, University of Berne, Länggass-Str. 122, CH-3012 Berne, Switzerland1
| | - William P Cheevers
- Department of Veterinary Microbiology and Pathology, College of Veterinary Medicine, Washington State University, Pullman, Washington 99164-7040, USA2
| | - Pierre Sonigo
- Génétique des Virus (ICGM-CNRS UPR 0415), Institut Cochin de Génétique moléculaire, 75014 Paris, France3
| | - Gianfranco Pancino
- Génétique des Virus (ICGM-CNRS UPR 0415), Institut Cochin de Génétique moléculaire, 75014 Paris, France3
| |
Collapse
|
16
|
Caldas APF, Leal ÉDS, Silva EFA, Ravazzolo AP. Detecção do provírus da Imunodeficiência Felina em gatos domésticos pela técnica de Reação em Cadeia da Polimerase. PESQUISA VETERINARIA BRASILEIRA 2000. [DOI: 10.1590/s0100-736x2000000100002] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
A infecção de gatos domésticos pelo Vírus da Imunodeficiência Felina (FIV) é um dos modelos mais promissores para o estudo da infecção pelo vírus da imunodeficiência humana (HIV) que causa a Síndrome de Imunodeficiência Adquirida (AIDS). O FIV causa, em gatos, uma enfermidade similar àquela observada em pacientes com AIDS, sobretudo no que diz respeito ao aumento da susceptibilidade a infecções oportunistas. No presente estudo, utilizou-se a Reação em Cadeia da Polimerase (PCR), com o objetivo de detectar o provírus do FIV em gatos com sinais clínicos de imunodeficiência. O fragmento de DNA escolhido como alvo para amplificação situa-se no gene gag do lentivírus felino, o qual é conservado entre as diferentes amostras do vírus. O DNA utilizado foi extraído a partir de amostras de sangue e de tecidos de animais com suspeita clínica de imunodeficiência. Das 40 amostras analisadas, 15 foram positivas, das quais 4 foram submetidas à hibridização, confirmando a especificidade dos fragmentos amplificados. Esses resultados demonstram a presença do FIV na população de gatos domésticos do Rio Grande do Sul, Brasil.
Collapse
|
17
|
Lerner DL, Elder JH. Expanded host cell tropism and cytopathic properties of feline immunodeficiency virus strain PPR subsequent to passage through interleukin-2-independent T cells. J Virol 2000; 74:1854-63. [PMID: 10644358 PMCID: PMC111663 DOI: 10.1128/jvi.74.4.1854-1863.2000] [Citation(s) in RCA: 37] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/16/2023] Open
Abstract
A cytopathic variant of feline immunodeficiency virus (FIV) strain PPR emerged after passage of wild-type virus on an interleukin-2-independent cell line. The virus, termed FIV-PPRglial, displayed a phenotype markedly different from the parental virus, including the ability to productively infect previously refractory cell lines, induction of large syncytia, and accelerated kinetic properties. A chimeric molecular clone, FIV-PPRchim42, containing the FIV-PPRglial envelope within the backbone of FIV-PPR, exhibited all the characteristics of the FIV-PPRglial phenotype, demonstrating that the viral envelope was responsible for the acquired traits. Subsequent molecular characterization revealed that the FIV-PPRglial envelope contained five amino acid substitutions relative to wild-type FIV-PPR. Mutagenic analyses further demonstrated that the acquired phenotype was minimally attributable to a combination of three mutations, specifically, a glutamine-to-proline change within the second constant domain of the surface protein (SU); a threonine-to-proline change within the V4 loop, also in the SU; and a premature stop codon in the cytoplasmic tail of the transmembrane protein. All three changes were required to produce the FIV-PPRglial phenotype. Cotransfection studies with mutant viruses in combination with each other and with FIV-PPR indicated that the truncated cytoplasmic tail was responsible for the induction of syncytium formation. Receptor usage analyses were pursued, and distinctions were observed between FIV-PPR and FIV-PPRglial. In vitro infections with FIV-PPR, FIV-PPRglial, and FIV-34TF10 on two adherent cell lines were ablated in the presence of SDF1alpha, the natural ligand for CXCR4. In contrast, viral infection of T cells was not limited to CXCR4 usage, and inhibition studies indicate the potential involvement of a CC chemokine receptor.
Collapse
Affiliation(s)
- D L Lerner
- Department of Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
| | | |
Collapse
|
18
|
Matteucci D, Pistello M, Mazzetti P, Giannecchini S, Isola P, Merico A, Zaccaro L, Rizzuti A, Bendinelli M. AIDS vaccination studies using feline immunodeficiency virus as a model: immunisation with inactivated whole virus suppresses viraemia levels following intravaginal challenge with infected cells but not following intravenous challenge with cell-free virus. Vaccine 1999; 18:119-30. [PMID: 10501242 DOI: 10.1016/s0264-410x(99)00189-9] [Citation(s) in RCA: 22] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The feline immunodeficiency virus (FIV) provides an excellent model system for AIDS vaccination studies. In the present experiments we investigated the immunogenicity and the protective activity of two inactivated vaccines prepared from a primary virus isolate. One vaccine was composed of whole virus inactivated with paraformaldehyde and then purified (WIV) and the other of viral proteins extracted with Tween-ether (TEV). Both vaccines elicited robust antiviral responses, but neither conferred appreciable levels of resistance against systemic challenge with the homologous virus. In addition, we tested whether the WIV vaccine, that had appeared more immunogenic, could protect against nontraumatic intravaginal exposure to FIV-infected cells. Although the proportions of control and vaccinated animals that became infected following mucosal challenge were similar, the vaccinees had significantly lower viral burdens than the controls, thus suggesting that immunisation with the WIV vaccine had limited FIV replication following intravaginal challenge.
Collapse
Affiliation(s)
- D Matteucci
- Department of Biomedicine, University of Pisa, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Pistello M, Matteucci D, Cammarota G, Mazzetti P, Giannecchini S, Del Mauro D, Macchi S, Zaccaro L, Bendinelli M. Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats. J Virol 1999; 73:1518-27. [PMID: 9882357 PMCID: PMC103976 DOI: 10.1128/jvi.73.2.1518-1527.1999] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The effects of preinfecting cats with a partially attenuated feline immunodeficiency virus (FIV) on subsequent infection with a fully virulent FIV belonging to a different subtype were investigated. Eight specific-pathogen-free cats were preinfected with graded doses of a long-term in vitro-cultured cell-free preparation of FIV Petaluma (FIV-P, subtype A). FIV-P established a low-grade or a silent infection in the inoculated animals. Seven months later, the eight preinfected cats and two uninfected cats were challenged with in vivo-grown FIV-M2 (subtype B) and periodically monitored for immunological and virological status. FIV-P-preinfected cats were not protected from acute infection by FIV-M2, and the sustained replication of this virus was accompanied by a reduction of FIV-P viral loads in the peripheral blood mononuclear cells and plasma. However, from 2 years postchallenge (p.c.) until 3 years p.c., when the experiment was terminated, preinfected cats exhibited reduced total viral burdens, and some also exhibited a diminished decline of circulating CD4(+) T lymphocytes relative to control cats infected with FIV-M2 alone. Interestingly, most of the virus detected in challenged cats at late times p.c. was of FIV-P origin, indicating that the preinfecting, attenuated virus had become largely predominant. By the end of follow-up, two challenged cats had no FIV-M2 detectable in the tissues examined. The possible mechanisms underlying the interplay between the two viral populations are discussed.
Collapse
Affiliation(s)
- M Pistello
- Retrovirus Center and Virology Section, Department of Biomedicine, University of Pisa, Pisa, Italy
| | | | | | | | | | | | | | | | | |
Collapse
|
20
|
Mazzetti P, Giannecchini S, Del Mauro D, Matteucci D, Portincasa P, Merico A, Chezzi C, Bendinelli M. AIDS vaccination studies using an ex vivo feline immunodeficiency virus model: detailed analysis of the humoral immune response to a protective vaccine. J Virol 1999; 73:1-10. [PMID: 9847300 PMCID: PMC103801 DOI: 10.1128/jvi.73.1.1-10.1999] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
The feline immunodeficiency virus (FIV) cat model is extensively used to investigate possible vaccination approaches against AIDS in humans. Although consistent levels of protection have been achieved with FIV, as with other model systems, by immunizing with whole inactivated virus or fixed infected cells, the mechanisms responsible for protection are elusive. In previous studies we showed that cats immunized with a vaccine consisting of fixed infected cells were protected or unprotected against cell-free or cell-associated FIV challenge depending on the time interval between completion of vaccination and challenge. In an attempt to define possible humoral immune correlates of protection, selected sera harvested at the times of challenge from such cats were examined for anti-FIV-antibody titers and properties by using binding and functional immunological assays. Binding assays included quantitative Western blotting, enzyme-linked tests for antibodies to FIV glycoproteins and immunodominant linear epitopes, and tests for measuring conformation dependence and avidity of anti-viral-envelope antibodies. Functional assays included virus neutralization performed with two different cell substrates, complement- and antibody-dependent virolysis, blocking of reverse transcriptase, and an assay that measured the ability of sera to prevent FIV growth in cocultures of infected and uninfected cells. Despite the wide spectrum of parameters investigated, no correlation between vaccine-induced protection and the humoral parameters measured was noted.
Collapse
Affiliation(s)
- P Mazzetti
- Department of Biomedicine and Retrovirus Center, University of Pisa, Pisa, Italy
| | | | | | | | | | | | | | | |
Collapse
|